Britain and America have secured a landmark trade agreement that will guarantee no import taxes on UK medicine shipments going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This move guarantees that duties on these key products will remain at nothing for a timeframe of three years.
This development follows recent threats to hike tariffs on patented drug imports, with potential rates mentioned reaching one hundred percent.
"This agreement between the UK strengthens the global environment for new treatments and introduces much-needed balance to transatlantic medicine commerce," a statement said.
Commercial Significance
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the America, which is by far the biggest destination for leading British pharmaceutical firms.
Trade data indicate that in the year prior to September, the UK shipped medicines totaling £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that span.
"This agreement secures work, boosts investment and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Previously, refunds topped 20%.
Recent Tensions
This agreement takes place against a ongoing row between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by assertions that US consumers were charged a premium for the identical medicines than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been directed toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the last ten years.
